FRANKLIN, Mass., Sept. 7 /PRNewswire-FirstCall/ -- Sontra Medical
Corporation (Nasdaq: SONTD) announced today that, following its recently
completed reverse stock split, it has regained compliance with the Nasdaq
Capital Market's $1.00 minimum bid price requirement for continued listing.
On August 11, 2006, Sontra completed a 1-for-10 reverse split of its Common
Stock and since such date the Company's Common Stock has traded under the
current symbol "SONTD". Effective at the opening of business on Monday,
September 11, 2006, the Company's Common Stock is expected to trade once
again under the symbol "SONT".
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation is a technology leader in transdermal
science and is developing a non-invasive, continuous transdermal glucose
monitor ("CTGM") for principal use in the Intensive Care Market. Through
its platform technology, the SonoPrep(R) Permeation System, combined with
technical competencies in transdermal drug formulation, analysis, delivery
systems and biosensors, the Company is creating a new paradigm in
transdermal drug delivery and diagnosis. The CTGM and other company
products are being developed for several billion dollar market
opportunities, all utilizing skin permeation, chemistry and biosensor
technology developed by the Company. In addition, the Company is developing
products for transdermal delivery of large molecule drugs and vaccines.
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and uncertainties. The
factors that could cause actual future results to differ materially from
current expectations include, but are not limited to, risks and
uncertainties relating to the Company's ability to develop, market and sell
products based on its technology, including a continuous transdermal
glucose monitor for the hospital ICU market; the expected size of the
market for the continuous transdermal glucose monitor for the hospital ICU
market; the expected benefits and efficacy of the SonoPrep device in
connection with diagnostics, vaccine delivery, glucose monitoring and
transdermal science; the availability of substantial additional funding to
conduct research and development, clinical studies and future product
commercialization; and, the Company's business, research, product
development, regulatory approval, marketing and distribution plans and
strategies. These and other factors are identified and described in more
detail in our filings with the SEC, including, without limitation, our
respective annual reports on Form 10-KSB for the year ended December 31,
2005, our most recent quarterly reports on Form 10-QSB, and our current
reports on Form 8-K. We do not undertake to update these forward-looking
statements made by us.
SonoPrep is a registered trademark of Sontra Medical Corporation. All
other company, product or service names mentioned herein are the trademarks
or registered trademarks of their respective owners.
Investor Relations Contact:
Harry G. Mitchell, CFO
508-530-0311
hmitchell@sontra.com
SOURCE Sontra Medical Corporation
 back to top
Related links:
http://www.sontra.com
CONTACT:
Harry G. Mitchell, CFO of Sontra Medical
Corporation, +1-508-530-0311, hmitchell@sontra.com
|
